The ABI2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma cell line HT29. This polyclonal product contains a heterogeneous mixture of cells carrying diverse loss-of-function mutations in the ABI2 gene, generated via CRISPR/Cas9-mediated gene disruption. The knockout model enables robust ablation of ABI2 adaptor protein expression, providing a physiologically relevant system for investigating actin cytoskeletal dynamics and tumor cell motility in a colorectal cancer background.
HT29 cells are an established adherent epithelial cell line originally isolated from a primary colorectal adenocarcinoma of a 44-year-old female. Widely employed as a model for colorectal cancer biology, these cells recapitulate key features of intestinal epithelial differentiation and drug response. Their genetic background and tumorigenic properties make them particularly suitable for metastasis and invasion assays, as well as for screening anti-cancer therapeutics targeting signal transduction pathways.
ABI2 (Abl interactor 2) encodes an adaptor protein that physically bridges Abl non-receptor tyrosine kinases (ABL1 and ABL2) to the WAVE regulatory complex (WRC). Acting downstream of Rac1 GTPase, ABI2 facilitates the activation of WAVE2 (WASF2) and the subsequent nucleation of actin filaments by the Arp2/3 complex. This pathway is critically regulated by upstream signals from Src family kinases, EGFR, and Abl kinases, which phosphorylate WRC components to modulate lamellipodia formation. Upon Rac1 activation, ABI2 orchestrates a multi-protein assembly involving NCK1, N-WASP, and WAVE2, thereby promoting localized actin polymerization at the leading edge. Consequently, knockout of ABI2 disrupts this cascade, impairing Rac1-driven actin reorganization and cell protrusion dynamics.
In HT29 colorectal adenocarcinoma cells, loss of ABI2 function is expected to severely attenuate migratory and invasive capabilities, as these processes are heavily dependent on ABI2-mediated actin remodeling. The polyclonal knockout population offers a robust loss-of-function model that avoids clonal artifacts inherent to single-cell-derived lines, thereby better representing the heterogeneous response of a tumor cell population. This model is therefore instrumental for deciphering the role of the Abl/WAVE axis in colorectal cancer metastasis and for evaluating anti-metastatic compounds targeting actin dynamics or upstream kinases.
Researchers can utilize these polyclonal ABI2 knockout cells in a wide array of functional assays, including wound healing and Boyden chamber invasion assays to quantify cell motility and invasiveness. Additionally, immunofluorescence staining for F-actin and live-cell imaging of lamellipodia dynamics allow direct visualization of actin cytoskeleton defects. Biochemical approaches such as western blotting for phospho-Abl and co-immunoprecipitation of WAVE complex components further enable dissection of signaling alterations. These cells are also suitable for drug response studies targeting EGFR or Abl kinases. For technical inquiries or custom applications, please contact Ascent Research.
